178 related articles for article (PubMed ID: 31679971)
1. 6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
Buckley BJ; Majed H; Aboelela A; Minaei E; Jiang L; Fildes K; Cheung CY; Johnson D; Bachovchin D; Cook GM; Huang M; Ranson M; Kelso MJ
Bioorg Med Chem Lett; 2019 Dec; 29(24):126753. PubMed ID: 31679971
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
3. Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Buckley BJ; Kumar A; Aboelela A; Bujaroski RS; Li X; Majed H; Fliegel L; Ranson M; Kelso MJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804289
[TBL] [Abstract][Full Text] [Related]
4. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?
Matthews H; Ranson M; Kelso MJ
Int J Cancer; 2011 Nov; 129(9):2051-61. PubMed ID: 21544803
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
7. 2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
Massey AP; Harley WR; Pasupuleti N; Gorin FA; Nantz MH
Bioorg Med Chem Lett; 2012 Apr; 22(7):2635-9. PubMed ID: 22366654
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
9. Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).
S El Salamouni N; Buckley BJ; Jiang L; Huang M; Ranson M; Kelso MJ; Yu H
J Med Chem; 2022 Feb; 65(3):1933-1945. PubMed ID: 34898192
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Ray P; Bhatti R; Gadarowski J; Bell N; Nasruddin S
Tumour Biol; 1998; 19(1):60-4. PubMed ID: 9422083
[TBL] [Abstract][Full Text] [Related]
11. Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
Buckley BJ; Aboelela A; Majed H; Bujaroski RS; White KL; Powell AK; Wang W; Katneni K; Saunders J; Shackleford DM; Charman SA; Cook GM; Kelso MJ; Ranson M
Bioorg Med Chem; 2021 May; 37():116116. PubMed ID: 33799173
[TBL] [Abstract][Full Text] [Related]
12. Amiloride selectively inhibits the urokinase-type plasminogen activator.
Vassalli JD; Belin D
FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
[TBL] [Abstract][Full Text] [Related]
14. Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
El Salamouni NS; Buckley BJ; Ranson M; Kelso MJ; Yu H
Biophys Rev; 2022 Feb; 14(1):277-301. PubMed ID: 35340592
[TBL] [Abstract][Full Text] [Related]
15. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Gladysz R; Adriaenssens Y; De Winter H; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
J Med Chem; 2015 Dec; 58(23):9238-57. PubMed ID: 26575094
[TBL] [Abstract][Full Text] [Related]
16. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
17. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
[TBL] [Abstract][Full Text] [Related]
18. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
[TBL] [Abstract][Full Text] [Related]
19. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Evans DM; Sloan-Stakleff KD
Invasion Metastasis; 1998-1999; 18(5-6):252-60. PubMed ID: 10729770
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the protease domain of urokinase-type plasminogen activator.
Rockway TW; Nienaber V; Giranda VL
Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]